__________________________________________________________________________________ Regd. Office: “Zydus Corporate Park” Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S.G. Highway, Ahmedabad – 382481. Phone: +91‐07971800000, +91‐79‐48040000 www.zyduscadila.com CIN: L24230GJ1995PLC025878 May 28, 2020 Listing Department Code: 532321 BSE Limited P J Towers, Dalal Street, Fort, Mumbai – 400001 Listing Department Code: CADILAHC NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 Re.: Notification Dear Sir / Madam, We hereby inform that the Company’s formulations manufacturing facility located at Baddi, India has received an Establishment Inspection Report (EIR). The EIR report stated that the classification of the facility is ‘No Action Indicated (NAI)’. The USFDA had conducted an inspection at the facility from 2nd to 9th March, 2020. The audit had ended with nil observations. FDA has concluded that this inspection is ''closed'' under 21 CFR 20.64(d)(3). We request you to bring this news to the notice of the members of the exchange and the investors at large. Thanking you, Yours faithfully, For, CADILA HEALTHCARE LIMITED DHAVAL N. SONI COMPANY SECRETARY
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
__________________________________________________________________________________
Regd. Office: “Zydus Corporate Park” Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S.G. Highway, Ahmedabad – 382481.
Phone: +91‐07971800000, +91‐79‐48040000 www.zyduscadila.com CIN: L24230GJ1995PLC025878
May 28, 2020 Listing Department Code: 532321 BSE Limited P J Towers, Dalal Street, Fort, Mumbai – 400001 Listing Department Code: CADILAHC NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 Re.: Notification
Dear Sir / Madam, We hereby inform that the Company’s formulations manufacturing facility located at Baddi, India has received an Establishment Inspection Report (EIR). The EIR report stated that the classification of the facility is ‘No Action Indicated (NAI)’. The USFDA had conducted an inspection at the facility from 2nd to 9th March, 2020. The audit had ended with nil observations. FDA has concluded that this inspection is ''closed'' under 21 CFR 20.64(d)(3). We request you to bring this news to the notice of the members of the exchange and the investors at large. Thanking you, Yours faithfully, For, CADILA HEALTHCARE LIMITED DHAVAL N. SONI COMPANY SECRETARY
Related Documents
